Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00002446
Other study ID # 305A
Secondary ID C97-331I97-331
Status Completed
Phase Phase 3
First received November 2, 1999
Last updated June 23, 2005
Start date August 1998

Study information

Verified date February 2000
Source NIH AIDS Clinical Trials Information Service
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety and effectiveness of 2 treatments for thrush (a fungal infection of the mouth and throat) in HIV-positive patients. Fluconazole is a drug that is commonly used to treat thrush. SCH 56592 is a new drug that will be compared to fluconazole.


Description:

Patients receive SCH 56592 oral suspension or fluconazole suspension for 14 days. Patients remain on study for 44 days total and are monitored for safety and efficacy of study treatment.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria

You may be eligible for this study if you:

- Are at least 18 years old.

- Are HIV-positive.

- Have thrush (oropharyngeal candidiasis).

- Agree to practice sexual abstinence or use effective barrier methods of birth control (e.g., condoms).

- Are able to take study medication and return for clinic visits during the study.

- Are expected to live for at least 2 months.

Exclusion Criteria

You will not be eligible for this study if you:

- Have received protease inhibitors for the first time within 30 days prior to study entry.

- Have received certain medications.

- Have certain other types of fungal infections.

- Have certain types of cancer.

- Have received SCH 56592 within 3 months prior to study entry.

- Are pregnant or breast-feeding.

- Cannot take medications by mouth.

- Are allergic to azole drugs.

- Have certain medical conditions.

- Have been in this study before.

Study Design

Endpoint Classification: Safety Study, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Posaconazole

Fluconazole


Locations

Country Name City State
Barbados Queen Elizabeth Hosp Respiratory Unit St Michael
United States East Bay AIDS Ctr Berkeley California
United States SUNY / Health Science Ctr at Brooklyn Brooklyn New York
United States UMDNJ - New Jersey Med School / Cooper Hosp Camden New Jersey
United States Med Univ of South Carolina Charleston South Carolina
United States TRIAD Health Practice Chicago Illinois
United States Amelia Ct Clinic Dallas Texas
United States Infectious Disease and AIDS Clinic Denver Colorado
United States Wayne State Univ / Harper Hosp Detroit Michigan
United States Community Hosp Indianapolis Indianapolis Indiana
United States Boulevard Comprehensive Care Ctr Jacksonville Florida
United States Jersey City Med Ctr Jersey City New Jersey
United States Miami Veterans Administration Med Ctr Miami Florida
United States Univ of Pennsylvania School of Dental Medicine Philadelphia Pennsylvania
United States Univ of Texas Health Sciences Ctr San Antonio Texas
United States Kaiser Foundation Hospital San Francisco California
United States ViRx Inc San Francisco California
United States Dupont Circle Physicians Group Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Schering-Plough

Countries where clinical trial is conducted

United States,  Barbados, 

See also
  Status Clinical Trial Phase
Completed NCT05454514 - Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS N/A
Completed NCT03760458 - The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age Phase 1/Phase 2
Completed NCT03141918 - Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS N/A
Completed NCT03067285 - A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study Phase 4
Recruiting NCT04579146 - Coronary Artery Disease (CAD) in Patients HIV-infected
Completed NCT06212531 - Papuan Indigenous Model of Male Circumcision N/A
Active, not recruiting NCT03256422 - Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients Phase 3
Completed NCT03256435 - Retention in PrEP Care for African American MSM in Mississippi N/A
Completed NCT00517803 - Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies N/A
Active, not recruiting NCT03572335 - Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
Completed NCT04165200 - Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV N/A
Recruiting NCT03854630 - Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection Phase 4
Terminated NCT03275571 - HIV, Computerized Depression Therapy & Cognition N/A
Completed NCT02234882 - Study on Pharmacokinetics Phase 1
Completed NCT01618305 - Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission Phase 4
Recruiting NCT05043129 - Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
Not yet recruiting NCT05536466 - The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine N/A
Recruiting NCT04985760 - Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy Phase 1
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Terminated NCT02116660 - Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) Phase 2